Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Dexrazoxane may reduce anthracycline cardiotoxicity in children; leaves open need for confirmatory randomized trials on long-term efficacy and safety.
Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1996.14.2.328 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8636739 Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. S E LipshultzxS E LipshultzSearch for articles by this author https://doi.org/10.1200/JCO.1996.14.2.328 First Page PDF © 1996 by American Society of Clinical Oncology
No takes yet. Share an insight, caveat, or question.
Steven E. Lipshultz (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: